JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

Home・Aktien・Microbot Medical Inc

Microbot Medical Inc

Open

1.79

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.76

Max

1.8399999999999999

Schlüsselkennzahlen
By Trading Economics
Einkommen	-77K -3.6M
Angestellte	20
EBITDA	-79K -3.6M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+386.11% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	23. März 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-11M 129M
Vorheriger Eröffnungskurs	1.79
Vorheriger Schlusskurs	1.79

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

2.52 / 2.57 Unterstützung & Widerstand

Microbot Medical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Feb. 2026, 23:52 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2. Feb. 2026, 23:52 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2. Feb. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2. Feb. 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2. Feb. 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2. Feb. 2026, 23:23 UTC

Ergebnisse

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2. Feb. 2026, 22:57 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2. Feb. 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2. Feb. 2026, 21:51 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Feb. 2026, 21:49 UTC

Ergebnisse

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2. Feb. 2026, 21:39 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:36 UTC

Ergebnisse

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2. Feb. 2026, 21:34 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2. Feb. 2026, 21:23 UTC

Ergebnisse

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2. Feb. 2026, 21:19 UTC

Ergebnisse

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2. Feb. 2026, 21:17 UTC

Ergebnisse

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2. Feb. 2026, 21:17 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:10 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:08 UTC

Ergebnisse

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2. Feb. 2026, 21:07 UTC

Ergebnisse

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q Net $608.7M >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q Rev $1.41B >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q Adj EPS 25c >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q EPS 24c >PLTR

2. Feb. 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Peer-Vergleich

Kursveränderung

Microbot Medical Inc Prognose

Kursziel

By TipRanks

386.11% Vorteil

12-Monats-Prognose

Durchschnitt 8.75 USD 386.11%

Hoch 12 USD

Tief 5.5 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Microbot Medical Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Microbot Medical Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

2.52 / 2.57Unterstützung & Widerstand

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.